← All trials
NCT05073718
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2022
- Primary completion
- Jan 1, 2023
- Completion date
- Oct 1, 2023
- First posted
- Oct 11, 2021
- Last posted
- Nov 17, 2021
- Enrollment
- 199
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BarcelonaLead sponsor
- University of BarcelonaCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- Hospital Universitario Infanta LeonorCollaborator
- Hospital Central de MaputoCollaborator
- University Hospital of TorrejonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.